Quick Answer
Metagenomi Therapeutics, Inc. reported Operating Income of -$96.01 million for fiscal year 2025.
Metagenomi Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$96.01M | -8.0% |
| 2024 | -$88.90M | -13.3% |
| 2023 | -$78.49M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$22.84M | -2.0% | -8.8% |
| June 30, 2025 | -$20.99M | -24.5% | +24.6% |
| March 31, 2025 | -$27.82M | +4.2% | -24.3% |
| September 30, 2024 | -$22.38M | +0.1% | -32.7% |
| June 30, 2024 | -$16.86M | +6.1% | +41.9% |
| March 31, 2024 | -$29.03M | -61.8% | -29.6% |
| September 30, 2023 | -$22.39M | — | -24.7% |
| June 30, 2023 | -$17.96M | — | -0.1% |
- Metagenomi Therapeutics, Inc. showed a decrease of -8.0% in Operating Income compared to the prior fiscal year.
- Over the 2023–2025 period, Metagenomi Therapeutics, Inc.’s operating income has declined by 22.3% (from -$78.49 million to -$96.01 million).
- The most recent figure is from Metagenomi Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: